Erratum: The promise of neuroprotective agents in Parkinson's disease by Stacey E. Seidl & Judith A. Potashkin
GENERAL COMMENTARY
published: 01 May 2013
doi: 10.3389/fnins.2013.00069
Erratum: The promise of neuroprotective agents in
Parkinson’s disease
Stacey E. Seidl1 and Judith A. Potashkin2*
1 The Department of Biological Sciences, DePaul University, Chicago, IL, USA
2 The Cellular and Molecular Pharmacology Department, The Chicago Medical School, RFUMS, North Chicago, IL, USA
*Correspondence: judy.potashkin@rosalindfranklin.edu
Edited by:
Nick Andrews, Children’s Hospital Boston, USA
Reviewed by:
Anders Haunso, Merck, UK
Zubair Ahmed, University of Birmingham, UK
A commentary on
The promise of neuroprotective agents in
Parkinson’s disease
by Seidl, S. E., and Potashkin, J. A., (2011).
Front. Neurol. 2:68. doi: 10.3389/fneur.
2011.00068
After our article was published online,
it was brought to our attention that in
Table 1 we incorrectly stated the find-
ings from a study testing the safety of
Isradipine (Simuni et al., 2010). We have
thus changed the text in the table to reflect
the results that Isradipine has been shown
to be safe andwell-tolerated in PDpatients.
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Table 1 | Neuroprotective Agents in PD models.
Neuroprotective
agents
Cell culture and animal studies Human and epidemiological studies
Study Results Study Results
Caffeine A (Van den Pol, 1986;
Kachroo et al., 2010)
A (Chen et al., 2001;
Joghataie et al., 2004;
Aguiar et al., 2006)
A (Joghataie et al., 2004;
Aguiar et al., 2006)
A (Xu et al., 2002, 2010)
A (Xu et al., 2006)
Decreased dopaminergic neuron
toxicity in MPTP
Decreased DA loss and restored
DA levels in MPTP and 6-OHDA
Decreased motor dysfunctions in
6-OHDA
Caffeine increased metabolites
associated with prevention of DA
loss
Estrogen and Caffeine prevented
neuroprotection
E (Ross et al., 2000; Ascherio
et al., 2001)*, Saaksjarvi et al.,
2008; Costa et al., 2010)*
E (Xu et al., 2006)
H (Ascherio et al., 2003)
Caffeinated beverages
decreased the risk of PD
Caffeinated beverages have
no effect on PD risk
A decrease in PD risk among
women consuming caffeine
and not taking hormone-
replacement therapy
Caffeine +
nicotine
A (Trinh et al., 2010) Decaffeinated coffee and
nicotine-free tobacco were
neuroprotective in Drosophila
E (Tan et al., 2003) Caffeine and nicotine
combined reduced the rate of
PD
Nicotine A (Ferger et al., 1998;
Costa et al., 2001)
A (Meshul et al., 2002)
A (Quik et al., 2006)
A (Carr and Rowell, 1990)*
Nicotine reduced DA depletion
resulting from MPTP and 6-OHDA
Nicotine minimized parkinsonian
contralateral rotations in 6-OHDA
Non-human primates maintained
dopaminergic function and cell
loss in the SNpc was prevented
with nicotine administartion
Tobacco smoke prior to MPTP
treatment reduced the loss of
striatal DA in mice
E (Quick, 2004; Simon et al.,
2009)
Nicotine lowered the risk of
developing PD
Urate and UA A/C (Jones et al., 2000;
Duan et al., 2002)
UA protects against DA-induced
apoptosis
E (de Lau et al., 2005, Annanmaki
et al., 2007, Chen et al., 2009),
(Alonso et al., 2007)*,
(Schwarzschild et al., 2008)*,
(Andreadou et al., 2009)*
H (Ascherio et al., 2009)
H (de Lau et al., 2005;
Schwarzschild et al., 2008)
Decreased risk of PD with UA
and urate
Slower rates of clinical
progression of PD were seen
with UA intake
Serum UA correlates with a
decreased risk of PD
Vitamin E A (Odunze et al., 1990)
A (Lan and Jiang, 1997;
Roghani and Behzadi,
2001)
A (Gong et al., 1991; Chi
et al., 1992)
C (Offen et al., 1996)
A (Perry et al., 1987)
Vitamin E deficiency increases
MPTP toxicity
Vitamin E supplimentation
protected DA neurons in the
SNpc and reduced DA loss
Striatal DA was not attenuated by
pretreatment of vitamin E
Vitamin E has no protective
effects against DA-induced
toxicity in PC12 cells
Vitamin E partially protected DA
neurons in MPTP rodents
E (Zhang et al., 2002; Etminan
et al., 2005)*
H (Fernandez-Calle et al., 1992;
LeWitt, 1994; Morens et al., 1996)
Protection from PD with
moderate Vitamin E intake
Clinical trials also show no
neuroprotective benefit of
taking vitamin E
(Continued)
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Table 1 | Continued
Neuroprotective
agents
Cell culture and animal studies Human and epidemiological studies
Study Results Study Results
Vitamin E +
vitamin C
H (Fahn, 1992) Both vitamins combined
decreased PD progression in
early stage patients
Vitamin C H (Scheider et al., 1997; Zhang
et al., 2002; Etminan et al., 2005)
H (Perlmutter, 1988)
Few beneficial effects are
seen with vitamin C and even
an increased risk of PD
Vitamin C intake reduced the
risk of PD by 40%
Vitamin D C (Butler et al., 2011)
H/A (Gash et al., 1996;
Kordower et al., 2000),
(Gill et al., 2003)
C/A (Wang et al., 2001;
Smith et al., 2006)
A (Holick, 2007)
Disruption of Vitamin D’s Ca2+
homeostasis properties
accelerated SNpc dopaminergic
neuron loss
GDNF stimulation by Vitamin D
can alleviated PD symptoms in
primates and PD patients
Vitamin D produced beneficial
effects against PD characteristics
Vitamin D increased
neuromuscular function in
parkinsonian rodents
E (Anderson et al., 1999) An increased risk of PD is
associated with high
consumption of vitamin D
Beta-carotene (Perry et al., 1985, 1987;
Yong et al., 1986)
Beta-carotene protected against
MPTP neurotoxicity in mice, but
not primates
E (Perlmutter, 1988) A decrease in the risk of PD
was seen with high
B-carotene intake
Riboflavin E (Perlmutter, 1988; Murakami
et al., 2010)
E (Coimbra and Junqueira, 2003)
Reduced risk of PD, with high
raboflavin intake by 51%
Riboflavin supplimentation
improved motor capacity of
PD patients
CoQ10 A (Shults et al., 1999)
A (Cleren et al., 2008)
CoQ10 protected nigrostriatal
dopaminergic neurons in MPTP
CoQ10 supplementation
diminished neural tissue damage
and prevented DA depletion in
SNpc
H (Shults et al., 2002; Shults,
2003; Galpern and Cudkowicz,
2007)
Investigators (2007)
Chronic administration of
CoQ10 delayed progression of
PD in patients with no adverse
affects in Phase II
Inconclusive results of CoQ10
supplement showing
neuroprotection in PD patients
CoQ10 +
vitamin E
H (Shults et al., 2004) Combination showed
beneficial for PD patients,
however, Phase III trials
deemed it futile (NINDS, see
text footnote 1)
Creatine A (Matthews et al., 1999) Creatine protected against
MPTP-induced DA depletion in
the SNpc
Investigators (2006)
Investigators (2008)
Creatine delayed the
progression of PD by 50%
Creatine showed efficacy as a
neuroprotective agent in PD
and is currently in Phase III
trials (NET-PDLS, see text
footnote 2)
CoQ10 +
creatine
A/H (Yang et al., 2009) Combination showed a
neuroprotective effect in chronic
MPTP and humans
(Continued)
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Table 1 | Continued
Neuroprotective
agents
Cell culture and animal studies Human and epidemiological studies
Study Results Study Results
DHA A (Bousquet et al., 2008)
C (Wang et al., 2003)
A (Ozsoy et al., 2011)
A (Samadi et al., 2006)
A (Bousquet et al., 2008)
DHA supplements replaced
omega-6 fatty acids after MPTP
Neurons were protected against
cytotoxicity with DHA intake
DHA decreased apoptosis of
dopaminergic cells in MPTP
DHA reduced 40% of the
levodopa-induced dyskinesias in
Parkinsonian primates
DHA preserved DA levels from
MPTP-induced neurotoxicity in
mice
DHA + uridine A (Wurtman et al., 2006;
Sakamoto et al., 2007)
A (Cansev et al., 2008)
This combination increased levels
of neural phosphatides, proteins in
synaptic membranes, and dendritic
spines in rodents
DHA and uridine administration
also reduced parkinsonian related
behaviors and elevated DA levels in
6-OHDA rats
Melatonin A (Acuna-Castroviejo et al.,
1997; Kim et al., 1998;
Maharaj et al., 2006a)
A (Mayo et al., 1998, 1999)
A (Tapias et al., 2010)
Neuronal cell death damage
induced by MPTP, 6-OHDA, and
iron was protected with Melatonin
administration
Melatonin blocked apoptosis and
necrosis in 6-OHDA and PC12 cells
Striatal DA depletion and DA
neuron loss increased after
melatonin treatment of
rotenone-induced Parkinsonism
H (Dowling et al., 2005) Melatonin improved duration
of sleep and reduced sleep
disturbances in PD patients
GSH A (Garrido et al., 2011)
C (Schulz et al., 2000)
A (Klivenyi et al., 2000)
A (Pileblad et al., 1989;
Seaton et al., 1996;
Wullner et al., 1996)
Excessive or reduced GSH levels
initiated degeneration of DA
neurons
Decreased GSH increased neuron
susceptibility to neurotoxins, but
did not correlate to DA viability or
striatal terminals
Depletion of DA was seen after
MPTP treatment in GSH
peroxidase-deficient mice
Low levels of GSH reduced DA
neurons after toxin administration
IP6 A/C (Xu et al., 2008, 2011)
A (Xu et al., 2008)
A (Obata, 2003)
IP6 inhibited MPTP, 6-OHDA, and
iron toxicity in cell culture
IP6 increased cell survival in MPTP
IP6 suppressed hydroxyl radical
formation after MPP+ treatment in
rats
(Continued)
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Table 1 | Continued
Neuroprotective
agents
Cell culture and animal studies Human and epidemiological studies
Study Results Study Results
NSAID
(ibuprofen+
aspirin)
A/C (Bilodeau et al., 1995;
Kaufmann et al., 1997;
Aubin et al., 1998; Saini
et al., 1998; Casper et al.,
2000; Sairam et al., 2003)
A/C (Esposito et al., 2007)
A (Casper et al., 2000;
Morioka et al., 2004;
Carrasco et al., 2005)
NSAID’s protected against
neuronal death and dopaminergic
neurotoxicity
NSAIDS showed neuroprotection
in MPTP, 6-OHDA, and in vitro
Ibuprofen protected DA neurons
against glutamate toxicity and
decreased MPTP toxicity
E (Chen et al., 2003; Ton et al.,
2006; Wahner et al., 2007; Gao
et al., 2011)
E (Chen et al., 2005; Ton et al.,
2006; Driver et al. 2011, Gao
et al., 2011)
E (Becker et al., 2011)
E (Bower et al., 2006; Hernan
et al., 2006)
E (Samii et al., 2009, Seroka,
2010)
NSAID’s lowered the risk of PD
A reduction in PD risk was
observed with Ibuprofen, but not
NSAIDS or Acetaminophen
NSAID’s and aspirin showed no
association with altering the risk
of PD
Increased risk of PD shown with
moderate aspirin intake
Ibuprofen reduced the risk of
developing PD in humans by 40%
Isradipine A (Ilijic et al., 2011) Isradipine showed neuroprotection
against 6-OHDA
H (Simuni et al., 2010) Isradipine has been shown to be
safe and well-tolerated in PD
patients
Phenylbutyrate C (Gardian et al., 2004;
Zhou et al., 2011)
A (Zhou et al., 2011)
Phenylbutyrate protected DA
neurons in the SNpc
Reduced deterioration in motor
and cognitive function in mice
Ex-4 A (Li et al., 2009)
A/C (Harkavyi et al., 2008;
Li et al., 2009)
Protected DA neuron
degeneration, preserved DA levels,
and improved motor function in
rodents
Ex-4 protected ventral
mesencephalic dopaminergic cells
in culture, reverse nigral lesions,
and protected against 6-OHDA
toxicity
Rasagiline C (Heikkila et al., 1985;
Huang et al., 1999; Speiser
et al., 1999; Maruyama
et al., 2000; Sagi et al.,
2001; Youdim et al., 2001a)
A (Kupsch et al., 2001,
Sagi et al., 2001).
A (Blandini et al., 2004)
C (Murer et al., 2001)
Reduces MPTP and 6-OHDA
toxicity in PC12 and SH-SY5Y cells
Rasagiline prevented nigrostriatal
damage induced by MPTP in
primates
Rasagiline increased DA neuron
survival in lesioned SNpc and
improved motor impairments
Rasagiline increased expression of
neurotrophins
H (Hauser et al., 2009; Olanow
et al., 2009)
H (Rascol et al., 2011)
Rasagiline reduced the long-term
progression and symptoms in PD
Rasagiline in a Phase III delayed
the need for antiparkinsonian
drugs and patients had lower
scores on the Parkinson’s disease
rating scale
Minocycline A/C (Du et al., 2001) Minocycline blocked
MPTP-induced degeneration of DA
neurons in the SNpc∼ preventing
loss of striatal DA and its
metabolites. Minocycline
treatment also inhibited MPP+
mediated inducible NO synthase
expression in vivo and blocked
NO-induced neurotoxicity in vitro
H (Investigators, 2006) Minocycline was deemed
effective in Phase II slowing the
progression of PD in patients.
An 18-month follow up study
showed no safety concerns with
its use (Investigators, 2008),
leading to Phase III trials
(Continued)
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Table 1 | Continued
Neuroprotective
agents
Cell culture and animal studies Human and epidemiological studies
Study Results Study Results
A (Faust et al., 2009;
Radad et al., 2010)
A (Quintero et al., 2006)
A/C (Yang et al., 2003)
A (Diguet et al., 2004)
DA neuroprotection by Minocycline
was seen in a Drosophila model of
PD and after rotenone toxicity in
rodents
Reduced the number of
apomorphine-induced rotations in
6-OHDA-lesioned rats
Minocycline exacerbated MPTP
damage to DA neurons in vitro and
in vivo
Minocycline treatment in primates
and mice produced more
severe/rapid parkinsonism,
behavior deficits, and greater loss
of nerve endings
Minocycline +
creatine
H (NET-PD, 2006) Reduced progression in PD
patients in Phase II
C, cell culture; A, animal; H, human; and E, epidemiological. Studies showing gender specificity, where males show favorable results are denoted (*).
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